Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GTW
|
|||
| Former ID |
DIB002811
|
|||
| Drug Name |
Fosdenopterin
|
|||
| Synonyms |
CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Molybdenum cofactor deficiency [ICD-11: 5B5K.A; ICD-10: E00-E90] | Approved | [1] | |
| Encephalopathy [ICD-11: 8E47; ICD-10: G93.4] | Phase 2 | [2] | ||
| Company |
Orphatec Pharmaceuticals GmbH
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C10H14N5O8P
|
|||
| Canonical SMILES |
C1C2C(C(C3C(O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
|
|||
| InChI |
1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1
|
|||
| InChIKey |
CZAKJJUNKNPTTO-AJFJRRQVSA-N
|
|||
| CAS Number |
CAS 150829-29-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:60210
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase (XDH) | Target Info | Cofactor | [1] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Guanosine nucleotides degradation | ||||
| Adenosine nucleotides degradation | ||||
| Retinoate biosynthesis II | ||||
| KEGG Pathway | Purine metabolism | |||
| Caffeine metabolism | ||||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Purine metabolism | ||||
| Pathwhiz Pathway | Caffeine Metabolism | |||
| Purine Metabolism | ||||
| Reactome | Purine catabolism | |||
| WikiPathways | Oxidative Stress | |||
| Effects of Nitric Oxide | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||
| REF 2 | ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.